Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inactivated SARS-CoV-2 vaccine + varicella vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This is a combination of two vaccines administered to provide immunity against both COVID-19 (caused by SARS-CoV-2) and varicella (chickenpox). The inactivated SARS-CoV-2 vaccine contains killed viral particles to stimulate an immune response without causing disease. The varicella vaccine is typically a live attenuated virus preparation that induces immunity against the varicella-zoster virus. Inactivated SARS-CoV-2 vaccines work by presenting the immune system with non-infectious viral antigens, leading to antibody production and cellular immunity. The primary indication for this combination is prevention of COVID-19 and chickenpox infection[1][6][7]. Developers and manufacturers may vary depending on region; for example, Varivax is a well-known brand name for the varicella component[6].
- Other names
- inactivated covid-19 vaccinechickenpox vaccinevaricella virus vaccine live
02
Targets
VZV glycoproteins (Varicella-zoster virus glycoproteins)SARS-CoV-2 spike
Beyond the preview
Go deeper on Inactivated SARS-CoV-2 vaccine + varicella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inactivated SARS-CoV-2 vaccine + varicella vaccine.